REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE? Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Special

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com SOURCE REGENXBIO Inc.
